Telesis Bio Q1 2024 Adj EPS $(5.52) Misses $(0.23) Estimate, Sales $3.440M Miss $6.900M Estimate
Portfolio Pulse from Benzinga Newsdesk
Telesis Bio (NASDAQ:TBIO) reported Q1 2024 adjusted EPS of $(5.52), significantly missing the $(0.23) estimate, with sales of $3.440M also missing the $6.900M estimate. This represents a 45.54% decrease in sales compared to the same period last year.
May 09, 2024 | 9:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Telesis Bio reported a significant miss in Q1 2024 earnings and sales, with EPS at $(5.52) against an $(0.23) estimate and sales of $3.440M vs. a $6.900M estimate.
The significant miss in both earnings per share and sales compared to analyst estimates, coupled with a substantial year-over-year decrease in sales, is likely to negatively impact investor sentiment and the stock price of Telesis Bio in the short term.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100